MX2024012104A - Formulaciones nasales estimulantes respiratorias - Google Patents
Formulaciones nasales estimulantes respiratoriasInfo
- Publication number
- MX2024012104A MX2024012104A MX2024012104A MX2024012104A MX2024012104A MX 2024012104 A MX2024012104 A MX 2024012104A MX 2024012104 A MX2024012104 A MX 2024012104A MX 2024012104 A MX2024012104 A MX 2024012104A MX 2024012104 A MX2024012104 A MX 2024012104A
- Authority
- MX
- Mexico
- Prior art keywords
- nasal formulations
- stimulating nasal
- respiratory stimulating
- respiratory
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263326578P | 2022-04-01 | 2022-04-01 | |
| PCT/US2023/017126 WO2023192602A2 (en) | 2022-04-01 | 2023-03-31 | Respiratory stimulant nasal formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024012104A true MX2024012104A (es) | 2025-01-09 |
Family
ID=88195037
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024012104A MX2024012104A (es) | 2022-04-01 | 2024-09-30 | Formulaciones nasales estimulantes respiratorias |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230310440A1 (https=) |
| EP (1) | EP4504206A4 (https=) |
| JP (1) | JP2025511227A (https=) |
| KR (1) | KR20240167901A (https=) |
| CN (1) | CN119630402A (https=) |
| AU (1) | AU2023241731A1 (https=) |
| CA (1) | CA3247210A1 (https=) |
| MX (1) | MX2024012104A (https=) |
| TW (1) | TW202345837A (https=) |
| WO (1) | WO2023192602A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2025511227A (ja) * | 2022-04-01 | 2025-04-15 | エナラーレ セラピューティクス インコーポレイテッド | 呼吸器刺激性経鼻製剤 |
| US20230414624A1 (en) * | 2022-06-24 | 2023-12-28 | Enalare Therapeutics Inc. | Methods of treating neurological ventilatory insufficiency |
| KR102882277B1 (ko) | 2023-11-22 | 2025-11-06 | 헤일러코리아 주식회사 | 구분된 공간을 구비하는 교체형 카트리지 및 이를 포함하는 네블라이징 디바이스 |
| KR102908992B1 (ko) | 2023-11-22 | 2026-01-14 | 박세진 | 네블라이징 디바이스용 교체형 카트리지 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2389530B (en) * | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| US20050053659A1 (en) * | 2003-09-10 | 2005-03-10 | Pace Gary W. | Methods and compositions for reducing the risk associated with the administration of opioid analgesics in patients with diagnosed or undiagnosed respiratory illness |
| US20120295911A1 (en) * | 2010-11-29 | 2012-11-22 | Galleon Pharmaceuticals, Inc. | Novel Compounds and Compositions for Treatment of Breathing Control Disorders or Diseases |
| AU2011336764B2 (en) * | 2010-11-29 | 2017-02-23 | Galleon Pharmaceuticals, Inc. | Novel compounds as respiratory stimulants for treatment of breathing control disorders or diseases |
| WO2012138797A1 (en) * | 2011-04-05 | 2012-10-11 | Amira Pharmaceuticals, Inc. | 3- or 5 - bi phenyl - 4 - ylisoxazole - based compounds useful for the treatment of fibrosis, pain, cancer and respiratory, allergic, nervous system or cardiovascular disorders |
| SG11201407964YA (en) * | 2012-05-29 | 2014-12-30 | Galleon Pharmaceuticals Inc | Novel compounds and compositions for treatment of breathing control disorders or diseases |
| US11903951B2 (en) * | 2016-06-03 | 2024-02-20 | M et P Pharma AG | Nasal pharmaceutical compositions with a porous excipient |
| WO2019182745A1 (en) * | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
| CA3141612A1 (en) * | 2019-05-22 | 2020-11-26 | Enalare Therapeutics Inc. | Methods and pharmaceutical compositions to treat drug overdose |
| CA3236586A1 (en) * | 2021-11-02 | 2023-05-11 | Joseph Pergolizzi | Methods of treating respiratory depression modulated by a non-opioid agent |
| JP2025511227A (ja) * | 2022-04-01 | 2025-04-15 | エナラーレ セラピューティクス インコーポレイテッド | 呼吸器刺激性経鼻製剤 |
-
2023
- 2023-03-31 JP JP2024558105A patent/JP2025511227A/ja active Pending
- 2023-03-31 US US18/129,538 patent/US20230310440A1/en active Pending
- 2023-03-31 CA CA3247210A patent/CA3247210A1/en active Pending
- 2023-03-31 KR KR1020247036038A patent/KR20240167901A/ko active Pending
- 2023-03-31 WO PCT/US2023/017126 patent/WO2023192602A2/en not_active Ceased
- 2023-03-31 EP EP23781876.0A patent/EP4504206A4/en active Pending
- 2023-03-31 AU AU2023241731A patent/AU2023241731A1/en active Pending
- 2023-03-31 TW TW112112709A patent/TW202345837A/zh unknown
- 2023-03-31 CN CN202380041882.3A patent/CN119630402A/zh active Pending
-
2024
- 2024-09-30 MX MX2024012104A patent/MX2024012104A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023192602A3 (en) | 2024-01-18 |
| CA3247210A1 (en) | 2023-10-05 |
| AU2023241731A1 (en) | 2024-10-31 |
| JP2025511227A (ja) | 2025-04-15 |
| WO2023192602A2 (en) | 2023-10-05 |
| US20230310440A1 (en) | 2023-10-05 |
| TW202345837A (zh) | 2023-12-01 |
| EP4504206A2 (en) | 2025-02-12 |
| KR20240167901A (ko) | 2024-11-28 |
| EP4504206A4 (en) | 2026-03-25 |
| CN119630402A (zh) | 2025-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024012104A (es) | Formulaciones nasales estimulantes respiratorias | |
| WO2022125616A8 (en) | Dialkyl tryptamines and their therapeutic uses | |
| CL2024002023A1 (es) | Inhibidor del inflamosoma nlrp3 y uso del mismo | |
| SA521430792B1 (ar) | مركبات مضادة للفيروسات محتوية على نيتريل | |
| MX2020007633A (es) | Péptidos macrocíclicos contra acinetobacter baumannii. | |
| NZ793536A (en) | Imidazolidinone derivatives and medical use thereof | |
| MX2021008247A (es) | Combinacion de dextrometorfano y bupropion para el tratamiento de depresion. | |
| MX2024001777A (es) | Derivado de sulfonamida, metodo de preparacion y uso medico del mismo. | |
| MX374497B (es) | Inhibidor del antígeno de superficie del virus de la hepatitis b. | |
| EA201071040A1 (ru) | Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1, cx3cr1 и p40 | |
| AR005053A1 (es) | Compuestos de difenilhexano, un procedimiento para su preparacion, composiciones farmaceuticas y el uso de dichos compuestos, y procedmientos para la manufactura de medicamentos para inhibir la infeccion de hiv | |
| MX2023006504A (es) | Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo. | |
| MX2024014861A (es) | Inhibidor de la prmt5 de tres anillos fusionados que contiene nitrogeno, y metodo de preparacion del mismo y uso farmaceutico del mismo | |
| MX2022015554A (es) | Moduladores de molecula peque?a de interleucina 17 (il-17). | |
| ZA202213687B (en) | Use of hpk1 kinase inhibitor in preventing and/or treating pathogen infection in animals | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| DOP2002000389A (es) | Metodo para fabricar una composición farmaceutica de dosis baja que tiene una distribución y potencia del fármaco uniforme | |
| CL2022002817A1 (es) | Inhibidores de replicación del virus de inmunodeficiencia humana | |
| CO2022008701A2 (es) | Uso y composición farmacéutica de derivados de fenilisoxazolil metilen-naftaleno-éter | |
| MX2022011016A (es) | Inhibidores de la replicacion del virus de inmunodeficiencia humana. | |
| MX2023009052A (es) | Compuesto de bifenilo como inmunomodulador, método de preparación para el mismo y uso del mismo. | |
| WO2021248254A3 (en) | Pharmacotherapeutic doses of hesperidin or related bioflavonoids to adress infectious and/or inflammatory diseases | |
| MX2021010834A (es) | Compuesto y metodo para la prevencion de transmision del virus de influenza. | |
| MX2023003846A (es) | Compuesto de bifenilo como inmunomodulador, metodo de preparacion del mismo y aplicacion del mismo. | |
| CO2026000927A2 (es) | Derivado de amida sustituido con heterociclilalquinilo, método de preparación del mismo y uso del mismo |